<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00459043</url>
  </required_header>
  <id_info>
    <org_study_id>06-283</org_study_id>
    <nct_id>NCT00459043</nct_id>
  </id_info>
  <brief_title>Docetaxel in Combination With Zactima (ZD6474) in Patients With Locally Advanced Squamous Cell Carcinoma of the the Head and Neck</brief_title>
  <official_title>Randomized Phase II Study of Docetaxel in Combination With Zactima (ZD6474) in Patients With Locally Advanced Squamous Cell Carcinoma of the Head and Neck</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Dana-Farber Cancer Institute</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Brigham and Women's Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Massachusetts General Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Loyola University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>AstraZeneca</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Dana-Farber Cancer Institute</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      In this research study, the researchers are comparing the combination of docetaxel and
      Zactima with docetaxel alone to see if the combination of the two drugs will be more
      effective than docetaxel alone. Zactima blocks the actions of three substances in the body:
      1)vascular endothelial growth factor reception (VEGFR); 2)epidermal growth factor receptor
      (EGFR); and 3) rearranged during transfection (RET). VEGFR stimulates the growth of new blood
      vessels. When certain proteins bind to the VEGF receptor, a process begins to occur which
      allows new blood vessels to be made that provide blood to the cancer cells. Zactima is
      thought to block these proteins from binding to the VEGF receptor, which would then block the
      process that creates new blood vessels. EGFR controls how quickly cells grow and multiply.
      RET is thought to have a particularly significant role in the development and growth of
      squamous cell tumors. The actions of Zactima are very different from the way standard
      chemotherapy drugs work. Researchers believe that Zactima might have different side effects
      from other cancer treatments so another one of the purposes of this study is to assess the
      side effects caused by the drug.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      -  Participants will be &quot;randomized&quot; into one of the following study groups: Docetaxel or
           Docetaxel with Zactima. Randomization means that participants will be put into a group
           by chance.

        -  The Docetaxel group will receive docetaxel on the first day of every treatment cycle,
           which lasts for 3 weeks. Even though treatment will occur once every three weeks,
           participants will return to the clinic on a weekly basis for the first two cycles. After
           the first two cycles, they will only have to return to the clinic at the start of each
           cycle.

        -  The combination Docetaxel and Zactima group will also receive docetaxel once every three
           weeks. In addition to the docetaxel, they will also take a Zactima pill orally every
           morning. They will also have to return to the clinic on a weekly basis just as those in
           the docetaxel only group.

        -  The following tests and procedures will be performed during each cycle of treatment,
           regardless of which group the participant is randomized into. These are considered
           standard of care for treating patients with chemotherapy for recurrent head and neck
           cancer: physical exams; blood tests; urine test; nasopharyngoscopy; repeat imaging of
           the tumor (x-ray, CT, MRI or PET); photographs of the tumor. In addition to the tests
           mentioned above, the Zactima group will have EKGs performed 3 times on the first day of
           treatment, once at week 2, then at the beginning of cycles 2 and 3, and then every 6
           weeks.

        -  Participants will continue on the study as long as they are receiving benefit and are
           not experiencing any unmanageable side effects.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>March 2007</start_date>
  <completion_date type="Actual">February 2012</completion_date>
  <primary_completion_date type="Actual">March 2010</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Partial Response Rate in Both Groups of Patients.</measure>
    <time_frame>3 years</time_frame>
    <description>Objective tumor response was evaluated radiogically using Response Evaluation Criteria in Solid Tumors (RECIST) version 1.0. For target lesions: Complete Response (CR) disappearance of all target lesions; Partial Response (PR) &gt;= 30% decrease in the sum of the longest diamter of target lesions; Overall Response (OR) = CR+PR</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Progression Free Survival</measure>
    <time_frame>3 years</time_frame>
    <description>Progression is defined using the Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.0) as a 20% increase in the sumof the longest diameter of target lesions, or a measurable increase in a non-target lesion or the appearance of new lesions</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Survival</measure>
    <time_frame>3 years</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">30</enrollment>
  <condition>Squamous Cell Carcinoma of Head and Neck</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Docetaxel Alone</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Docetaxel with ZD6474</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ZD6474</intervention_name>
    <description>Taken orally once every morning</description>
    <arm_group_label>2</arm_group_label>
    <other_name>Zactima</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Docetaxel</intervention_name>
    <description>Given on the first day of every treatment cycle (every 3 weeks)</description>
    <arm_group_label>1</arm_group_label>
    <arm_group_label>2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Histologically/cytologically documented SCCHN, excluding nasopharyngeal carcinoma.
             Squamous cell carcinomas of unknown primary are allowed. Primary salivary gland tumors
             and tumor of the nasal cavity and paranasal sinuses are not included.

          -  18 years of age or older.

          -  Evaluable or uni-dimensionally measurable local-regional and/or metastatic disease
             that is not amendable to primary surgical resection or radiotherapy.

          -  Life expectancy of at least 3 months.

          -  ECOG performance status of 0-2.

          -  Negative pregnancy test for women of childbearing potential.

          -  Adequate bone marrow function.

        Exclusion Criteria:

          -  Evidence of sever or uncontrolled systemic disease or any concurrent condition which
             in the investigator's opinion makes it undesirable for the patient to participate in
             the trial.

          -  Clinically significant cardiac event such as myocardial infarction, NYHA
             classification of heart disease grade II or higher within 3 months of study entry, or
             presence of cardiac disease that, in the opinion of the investigator, increases the
             risk of ventricular arrhythmia.

          -  History of arrhythmia which is symptomatic or requires treatment or asymptomatic
             sustained ventricular tachycardia. Atrial fibrillation, controlled on medication is
             not excluded.

          -  Previous history of QTc prolongation as a result from other medication that required
             discontinuation of that medication.

          -  Congenital long QT syndrome, or 1st degree relative with unexplained sudden death
             under 40 years of age.

          -  Presence of left bundle branch block.

          -  QTc with Bazett's correction that is unmeasurable or &gt; 480 msec on screening ECG.

          -  Any concomitant medication that may cause QTC prolongation, induce Torsades de Pointes
             or induce CYP3A4 function.

          -  Hypertension not controlled by medical therapy.

          -  Currently active diarrhea that may affect the ability of the patient to absorb
             Zactima.

          -  Pregnant or breast-feeding women.

          -  Previous or concurrent malignancies of other histologies within the last 5 years, with
             the exception of cervical carcinoma in-situ and adequately treated basal cell or
             squamous cell carcinoma of the skin.

          -  Receipt of any investigational agents within 30 days prior to commencing study
             treatment.

          -  Prior treatment with docetaxel.

          -  Last dose of prior chemotherapy discontinued less than 3 weeks before start of study
             therapy.

          -  Last dose of radiation therapy within the last 4 weeks before the start of study
             therapy, except palliative radiotherapy.

          -  Major surgery within 4 weeks, or incompletely healed surgical incision.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Robert Haddad, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Dana-Farber Cancer Institute</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Loyola University Medical Center/Cardinal Bernadin Cancer Center</name>
      <address>
        <city>Maywood</city>
        <state>Illinois</state>
        <zip>60153</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Massachusetts General Hospital</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02114</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dana-Farber Cancer Institute</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02115</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>July 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 10, 2007</study_first_submitted>
  <study_first_submitted_qc>April 10, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 11, 2007</study_first_posted>
  <results_first_submitted>February 28, 2013</results_first_submitted>
  <results_first_submitted_qc>July 1, 2013</results_first_submitted_qc>
  <results_first_posted type="Estimate">July 3, 2013</results_first_posted>
  <last_update_submitted>July 1, 2013</last_update_submitted>
  <last_update_submitted_qc>July 1, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 3, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Dana-Farber Cancer Institute</investigator_affiliation>
    <investigator_full_name>Robert I. Haddad, MD</investigator_full_name>
    <investigator_title>Medical Oncology</investigator_title>
  </responsible_party>
  <keyword>SCCHN</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Carcinoma, Squamous Cell</mesh_term>
    <mesh_term>Head and Neck Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Docetaxel</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>From March 2007 to October 2009, 30 patients were enrolled from four different sites in United States.</recruitment_details>
      <pre_assignment_details>Patients were randomized in a 1:1 ratio to receive docetaxel alone or docetaxel and vandetanib as combination therapy. No stratification at randomization was made for the study</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>1Docetaxel Single Agent</title>
          <description>Docetaxel 75 mg/m2 was administered every 21 days intravenously.</description>
        </group>
        <group group_id="P2">
          <title>2 Combination Docetaxel and ZD6474</title>
          <description>Docetaxel with ZD6474
Docetaxel 75 mg/m2 was administered every 21 days intravenously. ZD6474 (Vandetanib) at 100 mg was administered as a once daily tablet given orally.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="15"/>
                <participants group_id="P2" count="15"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="14"/>
                <participants group_id="P2" count="15"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>One patient withdrew consent after being randomized to docetaxel alone arm and did not receive any treatment, therefore, 29 patients were analyzable.</population>
      <group_list>
        <group group_id="B1">
          <title>Docetaxel Single Agent</title>
        </group>
        <group group_id="B2">
          <title>Combination of Docetaxel and Zactima</title>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="14"/>
            <count group_id="B2" value="15"/>
            <count group_id="B3" value="29"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="10"/>
                    <measurement group_id="B2" value="11"/>
                    <measurement group_id="B3" value="21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="56" spread="42"/>
                    <measurement group_id="B2" value="60" spread="35"/>
                    <measurement group_id="B3" value="58" spread="46"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="10"/>
                    <measurement group_id="B2" value="14"/>
                    <measurement group_id="B3" value="24"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="14"/>
                    <measurement group_id="B2" value="15"/>
                    <measurement group_id="B3" value="29"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Partial Response Rate in Both Groups of Patients.</title>
        <description>Objective tumor response was evaluated radiogically using Response Evaluation Criteria in Solid Tumors (RECIST) version 1.0. For target lesions: Complete Response (CR) disappearance of all target lesions; Partial Response (PR) &gt;= 30% decrease in the sum of the longest diamter of target lesions; Overall Response (OR) = CR+PR</description>
        <time_frame>3 years</time_frame>
        <population>29 patients were analyzable</population>
        <group_list>
          <group group_id="O1">
            <title>1Docetaxel Single Agent</title>
            <description>Docetaxel Alone</description>
          </group>
          <group group_id="O2">
            <title>2 Combination Docetaxel and ZD6474</title>
            <description>Docetaxel with ZD6474</description>
          </group>
        </group_list>
        <measure>
          <title>Partial Response Rate in Both Groups of Patients.</title>
          <description>Objective tumor response was evaluated radiogically using Response Evaluation Criteria in Solid Tumors (RECIST) version 1.0. For target lesions: Complete Response (CR) disappearance of all target lesions; Partial Response (PR) &gt;= 30% decrease in the sum of the longest diamter of target lesions; Overall Response (OR) = CR+PR</description>
          <population>29 patients were analyzable</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="14"/>
                <count group_id="O2" value="15"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7" lower_limit="0.2" upper_limit="33.8"/>
                    <measurement group_id="O2" value="13" lower_limit="1.6" upper_limit="40.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Progression Free Survival</title>
        <description>Progression is defined using the Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.0) as a 20% increase in the sumof the longest diameter of target lesions, or a measurable increase in a non-target lesion or the appearance of new lesions</description>
        <time_frame>3 years</time_frame>
        <group_list>
          <group group_id="O1">
            <title>1Docetaxel Single Agent</title>
            <description>Docetaxel Alone</description>
          </group>
          <group group_id="O2">
            <title>2 Combination Docetaxel and ZD6474</title>
            <description>Docetaxel with ZD6474</description>
          </group>
        </group_list>
        <measure>
          <title>Progression Free Survival</title>
          <description>Progression is defined using the Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.0) as a 20% increase in the sumof the longest diameter of target lesions, or a measurable increase in a non-target lesion or the appearance of new lesions</description>
          <units>weeks</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="14"/>
                <count group_id="O2" value="15"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.21" lower_limit="3.0" upper_limit="22.0"/>
                    <measurement group_id="O2" value="9" lower_limit="5.86" upper_limit="18.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Overall Survival</title>
        <time_frame>3 years</time_frame>
        <group_list>
          <group group_id="O1">
            <title>1Docetaxel Single Agent</title>
            <description>Docetaxel Alone</description>
          </group>
          <group group_id="O2">
            <title>2 Combination Docetaxel and ZD6474</title>
            <description>Docetaxel with ZD6474</description>
          </group>
        </group_list>
        <measure>
          <title>Overall Survival</title>
          <units>weeks</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="14"/>
                <count group_id="O2" value="15"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="26.8" lower_limit="17.7" upper_limit="100.7"/>
                    <measurement group_id="O2" value="24.1" lower_limit="16.4" upper_limit="171.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>1Docetaxel Single Agent</title>
          <description>Docetaxel Alone</description>
        </group>
        <group group_id="E2">
          <title>2 Combination Docetaxel and ZD6474</title>
          <description>Docetaxel with ZD6474</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="15"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Hemorrhage</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="15"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="14" subjects_at_risk="14"/>
                <counts group_id="E2" subjects_affected="15" subjects_at_risk="15"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Neutrophils</sub_title>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="14"/>
                <counts group_id="E2" subjects_affected="10" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>Hemoglobin</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="14"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>Neutrophils</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="14"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>Hemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="15"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Dysphagia</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="14"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="14"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>Diarrhea</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="14"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>Mucositis/Stomatitis</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="14"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>Anorexia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="14"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="15"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Pain</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="14"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="15"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Depression</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="14"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="15"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Alopecia</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="14"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>Rash</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="15"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Robert Haddad</name_or_title>
      <organization>DFCI</organization>
      <phone>6176326725</phone>
      <email>robert_haddad@dfci.harvard.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

